Drugs / BESIGLIPTIN
BESIGLIPTIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01984489 | Jun 2012 → May 2013 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BESIGLIPTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300558 ↗ |
| Known as | BESIGLIPTIN TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300558 ↗ |
| Known as | Shr-117887 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300558 ↗ |
| Known as | SHR117887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01984489 ↗ |
| Action | Inhibit | “SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor” NCT01984489 ↗ |
| Modality | Small molecule | — CHEMBL4300558 ↗ |